| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | SOUND PHARMACEUTICALS INC. | 4010 STONE WAY N | SEATTLE | WA | 98103-8099 | KING | USA | U01TR003853 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | 001 | 1 | NIH | 1/8/2024 | $0 |
| | 2024 | 2021 | SOUND PHARMACEUTICALS INC. | 4010 STONE WAY N | SEATTLE | WA | 98103-8099 | KING | USA | U01TR003853 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | 002 | 1 | NIH | 6/13/2024 | $0 |
| | 2024 | 2021 | SOUND PHARMACEUTICALS INC. | 4010 STONE WAY N | SEATTLE | WA | 98103-8099 | KING | USA | U01TR003853 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | 000 | 1 | NIH | 11/10/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,092,161 ) |
| | 2022 | 2022 | SOUND PHARMACEUTICALS INC. | 4010 STONE WAY N STE 120 | SEATTLE | WA | 98103-8099 | KING | USA | U01TR003853 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | 001 | 1 | NIH | 5/12/2022 | $0 |
| | 2022 | 2022 | SOUND PHARMACEUTICALS INC. | 4010 STONE WAY N STE 120 | SEATTLE | WA | 98103-8099 | KING | USA | U01TR003853 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | 000 | 1 | NIH | 5/11/2022 | $1,092,161 |
|
| Issue Date FY: 2021 ( Subtotal = $3,082,804 ) |
| | 2021 | 2021 | SOUND PHARMACEUTICALS INC. | 4010 STONE WAY N STE 120 | SEATTLE | WA | 98103-8099 | KING | USA | U01TR003853 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | 001 | 1 | NIH | 4/17/2021 | $0 |
| | 2021 | 2021 | SOUND PHARMACEUTICALS INC. | 4010 STONE WAY N STE 120 | SEATTLE | WA | 98103-8099 | KING | USA | U01TR003853 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | 000 | 1 | NIH | 4/6/2021 | $3,082,804 |
|
| Issue Date FY: 2003 ( Subtotal = $160,000 ) |
| | 2003 | 2003 | SOUND PHARMACEUTICALS INC | 4010 STONE WAY NORTH | SEATTLE | WA | 98103 | KING | USA | R43DC005928 | CELLULAR REGENERATION IN THE ORGAN OF CORTI | 000 | 1 | NIH | | $160,000 |
|
|
